Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia / Donald E. Addington en The Journal of Clinical Psychiatry, Año 2011 - Vol.72 - No.1 (Enero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No.1 (Enero) . - pp. 75-80 Título : Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia Tipo de documento: texto impreso Autores: Donald E. Addington, Autor ; Somaia Mohamed, Autor ; Robert A. Rosenheck, Autor Fecha de publicación: 2022 Artículo en la página: pp. 75-80 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Enfermedad crónica, Depresión, Trastorno depresivo mayor, Farmacoterapia, Perfenazina, Esquizofrenia. Resumen: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Link: ./index.php?lvl=notice_display&id=27929 [artículo] Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia [texto impreso] / Donald E. Addington, Autor ; Somaia Mohamed, Autor ; Robert A. Rosenheck, Autor . - 2022 . - pp. 75-80. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No.1 (Enero) . - pp. 75-80 Palabras clave: Antipsicóticos, Enfermedad crónica, Depresión, Trastorno depresivo mayor, Farmacoterapia, Perfenazina, Esquizofrenia. Resumen: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Link: ./index.php?lvl=notice_display&id=27929

---

1 (1 - 1 / 1)